Scancell Holdings Plc Scancell to speak at World Vaccine Congress Europe (4407Q)
18 Octubre 2023 - 1:00AM
UK Regulatory
TIDMSCLP
RNS Number : 4407Q
Scancell Holdings Plc
18 October 2023
18 October 2023
Scancell Holdings plc
("Scancell" or the "Company")
Scancell to present at the 2023 World Vaccine Congress
Europe
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies for the treatment of cancer and infectious disease,
today announces Professor Lindy Durrant, Chief Executive Officer
and Chief Scientific Officer of Scancell, will be presenting at the
2023 World Vaccine Congress Europe, taking place on 17-19 October
in Barcelona, Spain.
Prof Lindy Durrant, Chief Executive Officer and Chief Scientific
Officer of Scancell, commented: "Following the recent announcement
of positive data from the first stage in our Phase 2 SCOPE trial
with SCIB1 cancer vaccine for advanced melanoma, I am excited to
join other leading experts in the field to discuss the ongoing
clinical progress of our two lead cancer vaccine assets
SCIB1/iSCIB-1+ and Modi-1 at this prestigious forum within the
vaccine community."
The title, timing and location of the presentation are as
follows:
Presentation title Clinical update on the DC targeting melanoma
vaccine, SCIB1 and the Modi-1 vaccine targeting citrullination
Speaker Prof Lindy Durrant
Session date and time 11:00, 19 October 2023
Location Room 2
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3709 5700
Dr Jean-Michel Cosséry, Non-Executive Chairman
Professor Lindy Durrant, CEO
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) +44 (0) 20 7710 7600
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
ICR Consilium +44 (0) 20 3709 5700
Mary-Jane Elliott/Matthew Neal/Chris Welsh scancell@consilium-comms.com
About the SCOPE Phase 2 clinical trial
SCOPE is an open label, multicohort, multicentre, Phase 2 study
of SCIB1 in patients with advanced unresectable melanoma receiving
either nivolumab with ipilimumab or pembrolizumab. SCIB1 is a
deoxyribonucleic acid (DNA) plasmid vaccine encoding two CD8
epitopes from the melanoma antigens tyrosinase-related protein-2
and glycoprotein 100 (gp100), plus two CD4 epitopes from gp100. The
purpose of the study is to determine whether the addition of SCIB1
to standard of care checkpoint inhibitors can improve the objective
response rate (ORR) of patients with advanced melanoma relative to
the checkpoint inhibitors alone. The ORR is defined as the
proportion of patients with a complete or partial response at any
time after the start of treatment. During the first stage of the
SCOPE trial reported here, patients received SCIB1 in combination
with the best treatment currently available, namely the CPIs
nivolumab and ipilimumab. The First Stage milestone was protocolled
to demonstrate at least a 70% ORR with an 80% power ie at least
8/15 patients responding, assessed by radiological imaging. Further
information relating to the clinical trial can be found on the
Company's website at https://www.scancell.co.uk
and at
https://classic.clinicaltrials.gov/ct2/show/NCT04079166
About the ModiFY Phase 1/2 clinical trial
ModiFY is an open-label, multicohort, multicentre, adaptive
Phase 1/2 trial of Modi-1 in patients with unresectable HGSOC,
SCCHN, TNBC or RCC. The Modi-1 peptides are linked to AMPLIVANT(R)
, a potent adjuvant which is the subject of a worldwide licensing
and collaboration agreement with ISA Pharmaceuticals for the
manufacturing, development, and commercialisation of Modi-1. Modi-1
stimulates CD4 T cells which may directly impact tumour growth;
however, in some patients these T cells may need to be protected by
CPIs if the tumour environment is highly immunosuppressive.
Patients are therefore treated with Modi-1 alone or, if eligible
for standard of care CPI, with Modi-1 plus a CPI.
Cohort 1 of the study confirmed the safety profile of a low dose
of two citrullinated vimentin peptides. The objective for Cohort 2
of the trial was to assess the safety of the two citrullinated
vimentin peptides plus an enolase peptide at a higher dose. Based
on the safety data from Cohort 2, the ModiFY trial was expanded at
this recommended Phase 2 dose for Modi-1 monotherapy in all four
tumour types. In parallel, Cohort 3 recruited patients to receive
low dose Modi-1 plus a CPI to assess safety of the combination
prior to testing the higher dose of Modi-1 in Cohort 4.
Further information relating to the clinical trial can be found
on the Company's website at https://www.scancell.co.uk and at
https://clinicaltrials.gov/ct2/show/NCT05329532
About Scancell
Scancell is a clinical stage biopharmaceutical company that is
leveraging its proprietary research, built up over many years of
studying the human adaptive immune system, to generate novel
medicines to treat significant unmet needs in cancer and infectious
disease. The Company is building a pipeline of innovative products
by utilising its four technology platforms: Moditope (R) and
ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for
antibodies.
Adaptive immune responses include antibodies and T cells (CD4
and CD8), both of which can recognise damaged or infected cells. In
order to destroy such cancerous or infected cells, Scancell uses
either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique
approach is that its innovative products target modifications of
proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody
(R) ) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab(R) ) or enhances
the potency of antibodies and their ability to directly kill tumour
cells (AvidiMab (R) ).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFMFWWEDSEFS
(END) Dow Jones Newswires
October 18, 2023 02:00 ET (06:00 GMT)
Scancell (AQSE:SCLP.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Scancell (AQSE:SCLP.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
